Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 5/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7908480 | 0.80 | CYP2D6 (0.41) | CHRNB4CHRNA3LTA4H | |
| SCHEMBL7908483 | 0.80 | CYP2D6 (0.41) | CHRNB4CHRNA3LTA4H | |
| Hydrochloric Acid SCHEMBL7989937 | 0.78 | CYP2D6 (0.40) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| Hydrochloric Acid SCHEMBL7989933 | 0.78 | CYP2D6 (0.40) | CHRNB4CHRNA3CHRNB2CHRNA4LTA4H | |
| SCHEMBL14303748 | 0.73 | NCF1 (0.42) | CHRNB4CHRNA3HRH3 | |
| SCHEMBL25123168 | 0.71 | NCF1 (0.48) | HRH3 | |
| SCHEMBL12886704 | 0.71 | NCF1 (0.43) | HRH3 | |
| SCHEMBL24995091 | 0.69 | NCF1 (0.38) | HRH3 | |
| SCHEMBL10508008 | 0.69 | HTR1A (0.44) | — | |
| SCHEMBL24491426 | 0.69 | HTR1A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | CHRNB4 4683/4885CHRNA3 4603/4885CHRNB2 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.